Brian Kosobucki, MD
Ophthalmology · Winston Salem, NCNPI 1366548174
Payments from drug & device makers
Across 287 payments — averaging $36.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$9K
- Regeneron Healthcare Solutions, Inc.$512
- Mallinckrodt Hospital Products Inc.$363
- Alimera Sciences, Inc.$341
- AbbVie$230
- Bausch & Lomb, A Division Of Bausch Health US, LLC$143
- plus $416 from 11 others
What the payments were for
- Food & beverage$2,05493%
- Education$1497%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 216 | $8,598 |
| Regeneron Healthcare Solutions, Inc. | 7 | $512 |
| Mallinckrodt Hospital Products Inc. | 12 | $363 |
| Alimera Sciences, Inc. | 16 | $341 |
| AbbVie(2 entities) | 11 | $230 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $143 |
| Apellis Pharmaceuticals, Inc. | 3 | $54 |
| Bausch & Lomb Americas Inc. | 3 | $51 |
| ANI Pharmaceuticals, Inc. | 1 | $46 |
| Amgen | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Biogen | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Iridex Corporation | 1 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Alcon | 1 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$245
- Foresee Home$153
- EYLEA HD$114
How this compares
$10,603 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 82 | $57,813 |
| ProlensaBromfenac Sodium | 53 | $25,682 |
| Prednisolone Acetate | 767 | $25,171 |
| Ketorolac Tromethamine | 961 | $23,588 |
| RestasisCyclosporine | 21 | $16,842 |
| RhopressaNetarsudil Mesylate | 32 | $16,417 |
| Lotemax SmLoteprednol Etabonate | 49 | $14,008 |
| XiidraLifitegrast | 12 | $12,156 |
| Bromfenac Sodium | 34 | $9,722 |
| Loteprednol Etabonate | 70 | $9,380 |
| Difluprednate | 64 | $8,757 |
| Dexamethasone Sodium Phosphate | 217 | $8,019 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $6,895 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $6,112 |
| ValacyclovirValacyclovir Hcl | 125 | $5,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate | $143 | $49,070172 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $18 | $23,31253 claims |
| AbbVieRestasis | $230 | $16,84221 claims |
| Bausch & Lomb Americas Inc.Xiidra | $51 | $12,15612 claims |
| AlconSimbrinza | $28 | $6,11227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Winston Salem
- Rajiv ShahWinston Salem$1.3M
- Keith WalterWinston Salem$583K
- Craig GrevenWinston Salem$359K
- Vishak JohnWinston Salem$169K
- Jiaxi DingWinston Salem$43K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.